<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pharma 101 - Pharmaceutical Fraud &#187; Food and Drug Administration</title>
	<atom:link href="http://pharmaceutical-kickbacks.com/tag/food-and-drug-administration/feed/" rel="self" type="application/rss+xml" />
	<link>http://pharmaceutical-kickbacks.com</link>
	<description>Information &#38; Insight On Qui Tam Lawsuits Based Upon Unlawful Kickbacks, Marketing &#38; Pricing Conduct.</description>
	<lastBuildDate>Fri, 16 Dec 2011 21:42:34 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2</generator>
		<item>
		<title>FDA Launches Draft Guidelines On Financial Ties With Drug Companies</title>
		<link>http://pharmaceutical-kickbacks.com/fda-launches-draft-guidelines-on-financial-ties-with-drug-companies/</link>
		<comments>http://pharmaceutical-kickbacks.com/fda-launches-draft-guidelines-on-financial-ties-with-drug-companies/#comments</comments>
		<pubDate>Fri, 23 Mar 2007 17:24:14 +0000</pubDate>
		<dc:creator>Nolan and Auerbach</dc:creator>
				<category><![CDATA[Legal]]></category>
		<category><![CDATA[False Claims Act]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Food and Drug Administration]]></category>
		<category><![CDATA[U.S. Food and Drug Administration]]></category>
		<category><![CDATA[United States]]></category>

		<guid isPermaLink="false">http://pharmaceutical-kickbacks.com/?p=89</guid>
		<description><![CDATA[If an outside expert has more than $50,000 in ties to drug and medical device companies regulated by the Food and Drug Administration he will be barred from advising the FDA under the new draft guidelines. The money calculations include corporate grants, contracts, consulting fees and/or company stock.  Although it was not clear how many [...]]]></description>
			<content:encoded><![CDATA[<p>If an outside expert has more than $50,000 in ties to drug and medical device companies regulated by the Food and Drug Administration he will be barred from advising the FDA under the new draft guidelines. The money calculations include corporate grants, contracts, consulting fees and/or company stock.  Although it was not clear how many advisors would be disqualified, Randall Lutter, the Food and Drug Administration’s acring commissioner for policy, said it was a “significant number.”</p>
<p>To read more click <a href="http://www.msnbc.msn.com/id/17722620/" target="_blank" onclick="pageTracker._trackPageview('/outgoing/www.msnbc.msn.com/id/17722620/?referer=');">here</a>. To learn more about drug company inducements as a violation of the False Claims Act, click <a href="http://www.whistleblowerfirm.com/pharmaceutical-fraud/" target="_blank" onclick="pageTracker._trackPageview('/outgoing/www.whistleblowerfirm.com/pharmaceutical-fraud/?referer=');">here.<br />
</a></p>
<div class="zemanta-pixie" style="margin-top: 10px; height: 15px;"><span class="zem-script more-related"><script src="http://static.zemanta.com/readside/loader.js" type="text/javascript"></script></span></div>
]]></content:encoded>
			<wfw:commentRss>http://pharmaceutical-kickbacks.com/fda-launches-draft-guidelines-on-financial-ties-with-drug-companies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

